Abstract
We use longitudinal, disease-level data to analyze the impact of pharmaceutical innovation on longevity and medical expenditure in Sweden, where mean age at death increased by 1.88 years during the period 1997-2010. Pharmaceutical innovation is estimated to have increased mean age at death by 0.60 years during the period. The estimates indicate that longevity depends on the number of drugs to treat a disease, not the number of drug classes. Pharmaceutical innovation also reduced hospital utilization; the estimates indicate that an increase in the number of drugs commercialized for a disease reduces the number of hospital days due to the disease 8 years later, primarily due to its effect on the number of hospital discharges. The cost per life-year gained from the introduction of new drugs is estimated to be a small fraction of leading economists' estimates of the value of a 1-year increase in life expectancy.